Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sD-NP-GT8 + IL-12 DNA + Trimer 4571
- Development stage
- Unknown
- Lead developer
- HIV Vaccine Trials Network
- Modality
- DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
sD-NP-GT8 + IL-12 DNA + Trimer 4571 is an experimental HIV-1 vaccine regimen developed by the National Institute of Allergy and Infectious Diseases (NIAID). The regimen employs a germline-targeting strategy designed to induce broadly neutralizing antibodies (bNAbs) of the VRC01 class. It consists of a priming phase with synthetic DNA (sD) plasmids encoding the NP-GT8 immunogen (a multimeric protein displaying the VRC01-binding site) and Interleukin-12 (IL-12) as a genetic adjuvant. This is followed by a boosting phase with a stabilized recombinant HIV-1 envelope trimer, Trimer 4571, formulated with the TLR7/8 agonist adjuvant 3M-052-AF and alum. The combination is currently being evaluated in Phase 1 clinical trials (e.g., HVTN 305) for the prevention of HIV infection in healthy adults.
- Other names
- sD-NP-GT8 and IL-12 DNA HIV VaccinesD-NP-GT-8 and IL-12 DNA HIV VaccinesD-NP-GT 8 and IL-12 DNA HIV Vaccine
02
Targets
TLR7 (Toll-like receptor 7)IL-12R (Interleukin-12 receptor)BCR-HIV-Env (HIV-1 envelope-specific B-cell receptor)
Beyond the preview
Go deeper on sD-NP-GT8 + IL-12 DNA + Trimer 4571.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sD-NP-GT8 + IL-12 DNA + Trimer 4571.